CAS: 6740-87-0; 1-[c-(2-Chlorophenyl)-N-Methylcarbonimidoyl]Cyclopentan-1-Ol

该化合物是一个有机化合物,具有独特的结构特征,含有环戊甲醇混合物,有助于其循环结构和立体异构体学潜力;2-氯苯组的存在引入了可影响化合物反应和生物活动的卤素替代成分;甲基苯基功能组增加了其复杂性,表明氢与生物目标的结合和相互作用潜力;该化合物可能呈现出酒精和氨的典型特性,如极溶溶剂中的溶解性以及参与核分裂反应的能力;其具体特性,包括熔点,沸点和溶性,将取决于分子相互作用和研究该化合物的环境;

结构式图片

欧盟法规

C&L通报

上下游产品

(2-chlorophenyl)(cyclopentyl)methanone (+/-)-(2-chlorophenyl)(1-hydroxycyclopentyl)methanone methylamine (1-Brom°Cyclopentyl)(2-chlorophenyl)methanoneketamine N-(2-chlorophenylmethylene)methanamine (+/-)-ketamine hydr°Chloride (S)-ketamine

合成工艺路线路线简述

    📜邻氯苯腈置于12-冠醚-4,硼酸三异丙酯,碘,氧气,乙醇锂,Magnesium,亚磷酸三乙酯体系中,用 四氢呋喃,乙醇 作为反应溶剂,180.0 °C,1.7 Mpa 条件下,反应 21.25H,反应生成 氯氨酮相关物质a
    参考文献:在可持续的连续流动条件下方便地制备活性药物成分氯胺酮
    标题:在可持续的连续流动条件下方便地制备活性药物成分氯胺酮
    摘要:为有效和可持续地制备活性药物成分氯胺酮,提出了一种鲁棒的三步连续流动程序.该程序依靠连续流处理的主要资产,从可商购获得的化学药品开始,在强化条件下使用低毒性试剂和fda 3类溶剂.该程序具有独特的分子氧羟基化步骤,依靠硼酸三异丙酯的快速胺化以及采用蒙脱土k10作为非均相催化剂的热解法,所有这三个步骤均在乙醇中进行.这三个步骤可以独立运行,也可以串联在一起,从而为氯胺酮的生产提供了紧凑而有效的装置.在商业中试连续流反应器中评估了关键羟基化步骤的可扩展性.该方法也可以适用于氯胺酮类似物的制备.在热应力下对环戊基苯基酮骨架的骨架重排进行的全面计算研究合理化了实验选择性和本文报道的各种实验观察结果.
    DOI:10.1039/c9Gc00336C

    海关参考信息

    专利信息


    专利号:US-11718578-B2
    优先权日:2017-12-29
    标 题:Ketamine flow synthesis
    发明人:TOUPY THOMAS; GERARDY ROMARIC; MONBALIU JEAN-CHRISTOPHE; COLLIN DIEGO; KASSIN VICTOR-EMMANUEL
    权利人:UNIV LIEGE
    摘要:The invention provides a method for synthesizing a compound of formulawherein each R independently represents an optionally substituted aryl, heteroaryl, alkyl, perfluoroalkyl, cycloalkyl, alkoxy, aryloxy, acyl, carboxyl, hydroxyl, halogen, amino, nitro, cyano, sulfo or sulfhydryl group, in ortho, meta or para position to the cycloalkylamine moiety; R1 and R2 each independently represents a hydrogen atom, a lower alkyl group or a cycloalkyl group; R3 represents a hydrogen group, substituted aryl, heteroaryl, alkyl, perfluoroalkyl, cycloalkyl, alkoxy, aryloxy group; Y represents an oxygen atom, a sulfur atom, a NH group, a NR4 group or a CH2 group;R4 represents a hydrogen atom or an alkyl, aryl or a heteroaryl group; and n and m each independently represents an integer from 1 to 5; or a pharmaceutically acceptable salt thereof; or a precursor thereof; wherein the method comprises one or more of the following steps: (a) reacting a compound of formula (II)wherein R, R3, Y, n and m are as defined above in relation to the compound of formula (I) with an oxygenating agent, a first additive and a second additive in a solvent in a fluidic network or in a batch process under thermal and/or photochemical conditions to form a compound of formula (III):wherein R, R3, Y, n and m are as defined above in relation to the compound of formula (I), (b) reacting a compound of formula (III) with a nitrogen containing nucleophile in the presence of a third additive and/or a solvent in the fluidic network or in a batch process under thermal conditions to form a compound of formula (IV):wherein R, R1, R2, R3, Y, n and m are as defined above in relation to the compound of formula (I); and/or(c) reacting a compound of formula (IV) in a fluidic network or in a batch process, optionally in the presence of a fourth additive, under thermal conditions to form a compound of formula (I); wherein one or more of steps (a), (b) and/or (c) is carried out in a fluidic network that comprises micro- and/or meso-channels having an internal dimension of from 100 μm to 2000 μm.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D., Pharmaceutical Substances[Online], Thieme: Stuttgart, (2003).
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知